BR112018012884A2 - novos anticorpos anti-mmp16 e métodos de uso - Google Patents

novos anticorpos anti-mmp16 e métodos de uso

Info

Publication number
BR112018012884A2
BR112018012884A2 BR112018012884A BR112018012884A BR112018012884A2 BR 112018012884 A2 BR112018012884 A2 BR 112018012884A2 BR 112018012884 A BR112018012884 A BR 112018012884A BR 112018012884 A BR112018012884 A BR 112018012884A BR 112018012884 A2 BR112018012884 A2 BR 112018012884A2
Authority
BR
Brazil
Prior art keywords
methods
new anti
mmp16 antibodies
mmp16
antibodies
Prior art date
Application number
BR112018012884A
Other languages
English (en)
Inventor
Franklin Casey
Coelho David
Liu David
Saunders Laura
A Williams Samuel
J Dylla Scott
Roy Somdutta
Huang Zhao
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of BR112018012884A2 publication Critical patent/BR112018012884A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

são proporcionados novos anticorpos anti-mmp16 e conjugados de fárma-co-anticorpo e métodos de uso de tais anticorpos anti-mmp16 e conjugados de fár-maco-anticorpo para tratar o câncer.
BR112018012884A 2015-12-22 2016-12-21 novos anticorpos anti-mmp16 e métodos de uso BR112018012884A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562270846P 2015-12-22 2015-12-22
US201662433759P 2016-12-13 2016-12-13
PCT/US2016/068103 WO2017112803A1 (en) 2015-12-22 2016-12-21 Novel anti-mmp16 antibodies and methods of use

Publications (1)

Publication Number Publication Date
BR112018012884A2 true BR112018012884A2 (pt) 2018-12-04

Family

ID=59091191

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012884A BR112018012884A2 (pt) 2015-12-22 2016-12-21 novos anticorpos anti-mmp16 e métodos de uso

Country Status (10)

Country Link
US (1) US20190022242A1 (pt)
EP (1) EP3394106A1 (pt)
JP (1) JP2019506847A (pt)
CN (1) CN108431043A (pt)
AU (1) AU2016377669A1 (pt)
BR (1) BR112018012884A2 (pt)
CA (1) CA3009484A1 (pt)
MX (1) MX2018007817A (pt)
TW (1) TW201726748A (pt)
WO (1) WO2017112803A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107616979A (zh) * 2017-09-14 2018-01-23 湖南晓林生物科技发展有限公司 一种靶向治疗乳腺癌的药物及其应用
AU2019278870A1 (en) * 2018-05-30 2020-10-29 Abbvie Stemcentrx Llc Anti-SEZ6 antibody drug conjugates and methods of use
AU2021400733A1 (en) * 2020-12-16 2023-07-13 Memorial Sloan Kettering Cancer Center Cd40 binding molecules and uses thereof
EP4437002A1 (en) * 2021-11-22 2024-10-02 National Health Research Institutes Anti-hsp90? antibody and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
AU2007273507A1 (en) * 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
WO2009097397A2 (en) * 2008-01-30 2009-08-06 Dyax Corp. Metalloproteinase binding proteins
EP3633024A1 (en) * 2009-06-11 2020-04-08 Minerva Biotechnologies Corporation Methods for culturing stem and progenitor cells
US8710014B2 (en) * 2010-10-08 2014-04-29 Proteapex Therapeutics Llc Compositions and methods for inhibition of MMP13:MMP-substrate interactions
WO2013169890A1 (en) * 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis

Also Published As

Publication number Publication date
CA3009484A1 (en) 2017-06-29
US20190022242A1 (en) 2019-01-24
WO2017112803A1 (en) 2017-06-29
AU2016377669A1 (en) 2018-07-05
CN108431043A (zh) 2018-08-21
EP3394106A1 (en) 2018-10-31
MX2018007817A (es) 2019-09-05
JP2019506847A (ja) 2019-03-14
TW201726748A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
BR112019012343A2 (pt) anticorpos il-11ra
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
BR112018011319A2 (pt) novos anticorpos anti-claudina e métodos de uso
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112017018940A2 (pt) anticorpos sítio-específicos projetados e métodos de uso
BR112016016870A8 (pt) derivados de icariina, seus usos, e composição farmacêutica
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
EA201591709A1 (ru) 5-бром-индирубины
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
BR112017022682A2 (pt) construções de caliqueamicina e métodos de uso
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
BR112017010627A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
PL411685A1 (pl) Koniugat i jego zastosowanie

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]